Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesA phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites
Cancer Chemotherapy and Pharmacology, 07/03/08
Kuemmerle A et al. - Regional exposure to gemcitabine—the current standard drug for advanced adenocarcinoma of the pancreas—can be markedly enhanced using an optimised hypoxic stop-flow perfusion technique, with acceptable toxicities up to a dose of 1,125 mg/m^2. However, the activity of gemcitabine under hypoxic conditions is not as firmly established as that of other drugs such as mitomycin C, melphalan or tirapazamine. Further studies of this investigational modality, but with bioreductive drugs, are therefore warranted first to evaluate the tolerance in a phase I study and later on to assess whether it does improve the response to chemotherapy.
Related Articles
A Pilot Study for Combination Chemotherapy Using Gemcitabine and S-1 for Advanced Pancreatic Cancer
Oncology (Karger), 11/19/09
Relevance Score: 82%
In situ surgical procedures for locally advanced pancreatic cancer: partial abdominal evisceration and intestinal autotransplantation
Journal of Hepato-Biliary-Pancreatic Surgery, 11/12/09
Relevance Score: 81%
Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer
Journal of Clinical Oncology, 11/03/09
Relevance Score: 81%
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer
Journal of Clinical Oncology, 10/29/09
Relevance Score: 81%
Pancreatic Gout Masquerading as Pancreatic Cancer in a Heart Transplant Candidate
The Journal of Heart and Lung Transplantation, 10/07/09
Relevance Score: 81%
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics
Expert Opinion on Investigational Drugs, 12/16/09
Plerixafor for Stem Cell Mobilization in Patients with Non-Hodgkin's Lymphoma and Multiple Myeloma
Annals of Pharmacotherapy, 12/16/09
Clinically-Staged T3N0 Rectal Cancer: Is Preoperative Chemoradiotherapy the Optimal Treatment
Annals of Surgical Oncology, 12/16/09
Today in Pharmacokinetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Evaluation of Anti-HBs Serum Levels and Pharmacokinetic Profile After Intravenous Administration of Niuliva, a New Hepatitis B Immunoglobulin, Following Liver Transplantation
Transplantation Proceedings, 12/16/09
Which drug is effective and safe for acute malaria in pregnancy? Reviewing the evidence
Drug Development Research, 12/16/09
Pharmacokinetic Analysis of Hypoxia 18F-Fluoromisonidazole Dynamic PET in Head and Neck Cancer
The Journal of Nuclear Medicine, 12/16/09
Sponsor
Article Search
Sponsor
Sponsor